Piramal Pharma Share Price in Focus; Bayer Sales and Distribution Deal to End on December 31

Piramal Pharma’s existing commercial arrangement with Bayer Pharmaceuticals will come to an end at the close of December. The company said the arrangement, under which it provides sales and distribution support to Bayer, will not be renewed after its current term.  

The agreement will continue until December 31, 2026. Piramal Pharma and Bayer are also working through the activities covered under the arrangement to ensure the transition is completed smoothly.  

Arrangement Based on Distribution Support 

Under the agreement, Piramal Pharma handled sales and distribution support for Bayer and received commission-based income for the services. 

The company has not disclosed the exact amount of commission earned from the arrangement. It said the revenue linked to the business contributes less than 5% of its consolidated revenue.  

Piramal Pharma Sees Limited Financial Impact 

Piramal Pharma said it does not expect the non-renewal to have a material impact on its profitability or financial position. 

The company linked this assessment to the size and nature of the arrangement, noting that the income was commission-based.  

Bayer Arrangement Ends After Current Term 

There is no immediate change to the existing arrangement. It remains in place through December 31, after which the commercial relationship covered by the agreement will conclude. 

Read More: Aurobindo Pharma Share Price in Focus; Arm Acrotech Biopharma Launches ADQUEY Ointment in US! 

Piramal Pharma Share Price Performance  

As of 01 October 2026, Piramal Pharma Ltd share price closed at ₹198.30 per share, reflecting a decline of 3.98% from the previous trading session. 

Conclusion 

Piramal Pharma’s Bayer distribution arrangement will expire at the end of 2026 and will not continue into a new term. With the related revenue accounting for less than 5% of consolidated revenue, the company has said it does not expect the change to materially affect its financial position or profitability.  

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.